- Poster presentation
- Open Access
Reducing central line associated bacteraemia in intensive care units using low cost strategies
© Mclaws and Burrell; licensee BioMed Central Ltd. 2011
- Published: 29 June 2011
- Hand Hygiene
- Line Position
- Sterile Technique
- Preparation Strategy
Aseptic insertion technique of central lines has reduced Central line associated bacteremia (CLAB) using bundling of low cost patient and physician preparation strategies. Bundle compliance rates and survival analysis were used to illustrate improvements and gains in risk-free line-days.
36 adult ICUs in New South Wales, Australia implemented aseptic insertion bundles over 18-months. Patient bundle included 2% alcoholic chlorhexidine preparation of insertion site, full sterile sheet drape, line position checked with x-ray and/or transducer. Physician bundle included hand hygiene, hat, mask, eyewear, sterile gloves/gown, maintain sterile technique. The first 12-month roll-out period was used to train all ICU physicians to implement the bundles and collect data. 10,575 lines inserted were followed until discharged from ICU. CLAB rates and bundle compliance rates were calculated quarterly and survival analysis established the CLAB-free line-day period.
The CLAB rate was significantly reduced from 3.0/1000 line-days in the first 12-months to 1.2/1000 line-days in the last 6-months (P=0.0006). Compliance with both physician and patient bundles reduced CLAB (RR 0.5, 95%CI 0.4-0.8, P=0.004) compared with non compliance while non compliance with the physician bundle increased the risk of CLAB (RR 1.62, 95%CI 1.1-2.4, P=0.0178). The CLAB rate was 3.8/1000 (95%CI 2.5-5.5) line-days in the first 12-months and was significantly reduced by the last 6 months (1.6/1000 line-days, 95%CI 1.0-2.4). CLAB commenced at day-7 (1.8/1000 line days) in the first 12-months but did not occur until day-9 (0.9/1000 line-days) by the last 6 months.
CLAB is essentially preventable with a highly effective low cost aseptic insertion technique that enables patients to remain risk-free for the first 9 line-days.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.